Shehnaaz Suliman Sells 5,723 Shares of 10x Genomics (NASDAQ:TXG) Stock

Posted by Brenda Bartman on Jun 20th, 2026

10x Genomics (NASDAQ:TXG – Get Free Report) Director Shehnaaz Suliman sold 5,723 shares of the business’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $32.63, for a total transaction of $186,741.49. Following the completion of the sale, the director owned 31,722 shares in the company, valued at $1,035,088.86. This represents a 15.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

10x Genomics Price Performance

TXG stock opened at $34.76 on Friday. 10x Genomics has a 52 week low of $10.48 and a 52 week high of $35.65. The company has a fifty day simple moving average of $25.61 and a two-hundred day simple moving average of $21.50. The firm has a market capitalization of $4.41 billion, a P/E ratio of -204.47 and a beta of 2.12.

10x Genomics (NASDAQ:TXG – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.19. 10x Genomics had a negative net margin of 3.55% and a negative return on equity of 2.86%. The business had revenue of $150.84 million during the quarter, compared to analysts’ expectations of $146.41 million. During the same period last year, the company posted ($0.28) EPS. The business’s revenue was up 9.4% on a year-over-year basis. As a group, analysts anticipate that 10x Genomics will post -0.79 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on TXG shares. Morgan Stanley boosted their price objective on 10x Genomics from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Tuesday, May 12th. Canaccord Genuity Group lifted their target price on 10x Genomics from $22.00 to $32.00 and gave the stock a “buy” rating in a report on Monday, April 20th. Zacks Research cut 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. UBS Group boosted their target price on 10x Genomics from $14.00 to $20.00 and gave the company a “neutral” rating in a research report on Friday, February 20th. Finally, JPMorgan Chase & Co. increased their price target on 10x Genomics from $17.00 to $20.00 and gave the company a “neutral” rating in a report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, 10x Genomics presently has a consensus rating of “Hold” and an average price target of $23.17.

Get Our Latest Stock Report on 10x Genomics

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in TXG. Geneos Wealth Management Inc. purchased a new stake in 10x Genomics in the 4th quarter valued at about $38,000. Larson Financial Group LLC increased its position in shares of 10x Genomics by 164.4% during the fourth quarter. Larson Financial Group LLC now owns 2,364 shares of the company’s stock worth $39,000 after acquiring an additional 1,470 shares during the period. Fifth Third Bancorp purchased a new position in shares of 10x Genomics during the first quarter worth approximately $50,000. Van ECK Associates Corp raised its stake in shares of 10x Genomics by 85.9% during the fourth quarter. Van ECK Associates Corp now owns 3,668 shares of the company’s stock valued at $60,000 after acquiring an additional 1,695 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its stake in shares of 10x Genomics by 203.9% during the second quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock valued at $87,000 after acquiring an additional 5,025 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

10x Genomics Company Profile

(Get Free Report)

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.